ATE251618T1 - 3-(arylsulfonylamino)-tetrahydrofuran-3- carbonsäure-hydroxamide - Google Patents

3-(arylsulfonylamino)-tetrahydrofuran-3- carbonsäure-hydroxamide

Info

Publication number: ATE251618T1
Authority: AT; Austria
Prior art keywords: cancer; arylsulfonylamino; tetrahydrofuran; carboxylic acid; treatment
Prior art date: 1999-05-28

Application number

AT00922821T

Other languages

English (en)

Inventor

Lawrence Alan Pfizer In Reiter

Road

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-28

Filing date

2000-05-15

Publication date

2003-10-15

2000-05-15 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-10-15 Application granted granted Critical

2003-10-15 Publication of ATE251618T1 publication Critical patent/ATE251618T1/de

Links

206010028980 Neoplasm Diseases 0.000 abstract 5
201000011510 cancer Diseases 0.000 abstract 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
206010009944 Colon cancer Diseases 0.000 abstract 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 abstract 1
208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
206010025323 Lymphomas Diseases 0.000 abstract 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
229930012538 Paclitaxel Natural products 0.000 abstract 1
229940009456 adriamycin Drugs 0.000 abstract 1
229930013930 alkaloid Natural products 0.000 abstract 1
229940035676 analgesics Drugs 0.000 abstract 1
239000000730 antalgic agent Substances 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
208000029742 colonic neoplasm Diseases 0.000 abstract 1
238000002648 combination therapy Methods 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
229960005420 etoposide Drugs 0.000 abstract 1
230000009033 hematopoietic malignancy Effects 0.000 abstract 1
208000032839 leukemia Diseases 0.000 abstract 1
201000005202 lung cancer Diseases 0.000 abstract 1
208000020816 lung neoplasm Diseases 0.000 abstract 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
229910052697 platinum Inorganic materials 0.000 abstract 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
229940063683 taxotere Drugs 0.000 abstract 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
229960004528 vincristine Drugs 0.000 abstract 1
-1 vincristine Natural products 0.000 abstract 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
AIDS & HIV (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Tropical Medicine & Parasitology (AREA)
Psychology (AREA)

AT00922821T 1999-05-28 2000-05-15 3-(arylsulfonylamino)-tetrahydrofuran-3- carbonsäure-hydroxamide ATE251618T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13667799P	1999-05-28	1999-05-28
PCT/IB2000/000646 WO2000073294A2 (en)	1999-05-28	2000-05-15	3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides

Publications (1)

Publication Number	Publication Date
ATE251618T1 true ATE251618T1 (de)	2003-10-15

Family

ID=22473882

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00922821T ATE251618T1 (de)	1999-05-28	2000-05-15	3-(arylsulfonylamino)-tetrahydrofuran-3- carbonsäure-hydroxamide

Country Status (19)

Country	Link
US (1)	US6342521B1 (de)
EP (1)	EP1181285B1 (de)
JP (1)	JP3828748B2 (de)
AT (1)	ATE251618T1 (de)
AU (1)	AU4309800A (de)
BR (1)	BR0011538A (de)
CA (1)	CA2375513C (de)
DE (1)	DE60005818T2 (de)
DK (1)	DK1181285T3 (de)
ES (1)	ES2203456T3 (de)
GT (1)	GT200000084A (de)
HN (1)	HN2000000052A (de)
MA (1)	MA26737A1 (de)
MX (1)	MXPA01012266A (de)
PE (1)	PE20010204A1 (de)
PT (1)	PT1181285E (de)
TN (1)	TNSN00114A1 (de)
UY (1)	UY26169A1 (de)
WO (1)	WO2000073294A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP4343373B2 (ja) *	2000-01-14	2009-10-14	富士フイルム株式会社	写真サービスシステム及びデジタルカメラ
NZ520657A (en)	2000-03-21	2004-11-26	Procter & Gamble	Heterocyclic side chain containing, N-substituted metalloprotease inhibitors
WO2001070693A2 (en)	2000-03-21	2001-09-27	The Procter & Gamble Company	Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
NZ520656A (en) *	2000-03-21	2004-05-28	Procter & Gamble	Heterocyclic side chain containing metalloprotease inhibitors
US6548539B1 (en) *	2001-03-05	2003-04-15	Avalon Pharmaceuticals	Agents for regulation of colon cancer gene expression
GB0319069D0 (en) *	2003-08-14	2003-09-17	Glaxo Group Ltd	Therapeutically useful compounds
RU2291497C1 (ru) *	2005-06-28	2007-01-10	Институт биомедицинских исследований Владикавказского научного центра РАН и Правительства РСО-Алания (ИБМИ ВНЦ РАН)	Способ лечения рака молочной железы в эксперименте
PE20120008A1 (es) *	2009-01-12	2012-01-24	Icagen Inc	Derivados de fenoxi bencenosulfonamida
JP5872552B2 (ja)	2010-07-09	2016-03-01	ファイザー・リミテッドＰｆｉｚｅｒＬｉｍｉｔｅｄ	化学化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5455258A (en) *	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5663357A (en) *	1995-11-22	1997-09-02	Allergan	Substituted heteroarylamides having retinoid-like biological activity
PL334846A1 (en) *	1997-01-23	2000-03-27	Hoffmann La Roche	Sulphamidic inhibitors of metaloproteases
NZ336840A (en) *	1997-02-03	2001-01-26	Pfizer Prod Inc	Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
WO1999002510A1 (en) *	1997-07-10	1999-01-21	Pharmacia & Upjohn S.P.A.	Matrix metalloproteinase inhibitors
CA2298617A1 (en) *	1997-07-31	1999-02-11	Yetunde Olabisi Taiwo	Acyclic metalloprotease inhibitors

2000
- 2000-04-12 HN HN2000000052A patent/HN2000000052A/es unknown
- 2000-05-15 BR BR0011538-0A patent/BR0011538A/pt not_active IP Right Cessation
- 2000-05-15 PT PT00922821T patent/PT1181285E/pt unknown
- 2000-05-15 AU AU43098/00A patent/AU4309800A/en not_active Abandoned
- 2000-05-15 DK DK00922821T patent/DK1181285T3/da active
- 2000-05-15 MX MXPA01012266A patent/MXPA01012266A/es active IP Right Grant
- 2000-05-15 EP EP00922821A patent/EP1181285B1/de not_active Expired - Lifetime
- 2000-05-15 CA CA002375513A patent/CA2375513C/en not_active Expired - Fee Related
- 2000-05-15 ES ES00922821T patent/ES2203456T3/es not_active Expired - Lifetime
- 2000-05-15 WO PCT/IB2000/000646 patent/WO2000073294A2/en not_active Ceased
- 2000-05-15 AT AT00922821T patent/ATE251618T1/de not_active IP Right Cessation
- 2000-05-15 DE DE60005818T patent/DE60005818T2/de not_active Expired - Fee Related
- 2000-05-15 JP JP2000621360A patent/JP3828748B2/ja not_active Expired - Fee Related
- 2000-05-24 MA MA25987A patent/MA26737A1/fr unknown
- 2000-05-24 TN TNTNSN00114A patent/TNSN00114A1/fr unknown
- 2000-05-25 US US09/578,661 patent/US6342521B1/en not_active Expired - Fee Related
- 2000-05-26 GT GT200000084A patent/GT200000084A/es unknown
- 2000-05-26 UY UY26169A patent/UY26169A1/es not_active Application Discontinuation
- 2000-05-26 PE PE2000000510A patent/PE20010204A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
PT1181285E (pt)	2004-01-30
EP1181285A2 (de)	2002-02-27
CA2375513C (en)	2006-11-28
EP1181285B1 (de)	2003-10-08
MXPA01012266A (es)	2002-07-30
DE60005818D1 (de)	2003-11-13
MA26737A1 (fr)	2004-12-20
TNSN00114A1 (fr)	2002-05-30
BR0011538A (pt)	2002-02-26
JP3828748B2 (ja)	2006-10-04
GT200000084A (es)	2001-11-17
CA2375513A1 (en)	2000-12-07
PE20010204A1 (es)	2001-03-05
US6342521B1 (en)	2002-01-29
JP2003500484A (ja)	2003-01-07
ES2203456T3 (es)	2004-04-16
DE60005818T2 (de)	2004-05-06
AU4309800A (en)	2000-12-18
WO2000073294A2 (en)	2000-12-07
WO2000073294A3 (en)	2001-03-29
UY26169A1 (es)	2000-12-29
HN2000000052A (es)	2001-02-02
DK1181285T3 (da)	2004-01-26

Legal Events

Date

Code

Title

Description

2004-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1181285

Country of ref document: EP

2008-02-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE297908T1 (de)	2005-07-15	Tace inhibitoren
AP2001002070A0 (en)	2001-03-31	Hydroxy pipecolate hydroxamic acid derivatives as MMP Inhibitors.
MY121754A (en)	2006-02-28	Arylsulfonylamino hydroxamic acid derivatives
EA199900641A1 (ru)	2000-04-24	Производные арилсульфонилгидроксамовой кислоты
ATE251618T1 (de)	2003-10-15	3-(arylsulfonylamino)-tetrahydrofuran-3- carbonsäure-hydroxamide
NO20025792D0 (no)	2002-12-02	Kinazolinderivater for behandling av tumorer
NO990821L (no)	1999-02-23	Arylsulfonylamino-hydroksaminsyre-derivater
CA2428160A1 (en)	2002-05-10	Compositions for antitumor treatment containing ecteinascidin 743
GEP20084376B (en)	2008-05-27	Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same
DK1181286T3 (da)	2004-02-16	3-(arylsulfonylamino)-tetrahydropyran-3-carboxylsyre hydroxamider
IT8323359A0 (it)	1983-10-19	Complessi platino-diamminici, procedimento per la loro preparazione, procedimento per lapreparazione di una composizione medica contenente tali complessi platino-diamminici per il trattamento del cancro, nonche'composizione cosi' realizzata.
FI1496918T3 (fi)	2023-05-11	Natriummeta-arseniitin käyttö kasvainten hoidossa
YU46302A (sh)	2005-06-10	Supstituisani piroli
ECSP003494A (es)	2001-12-28	Hidroxiamidas de acidos 3- ( arilsulfonilamino)-tetrahidropiran-3-carboxilicos
PT1202992E (pt)	2004-12-31	Derivados de ascididemina e suas aplicacoes terapeuticas